[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100556900":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":33,"centralContacts":38,"locations":48,"responsibleParty":66,"collaborators":42,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":42,"eligibilityCriteria":75,"healthyVolunteers":71,"sex":76,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":42,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":51,"whyStopped":42,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"Kafrelsheikh University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"apixaban","ACTIVE_COMPARATOR","100 CVT patients will receive apixaban 5mg Bid for 6 months",[13],"Drug: Apixaban 5MG",{"label":15,"type":10,"description":16,"interventionNames":17},"rivaroxaban","100 CVT patients will receive rivaroxaban 20mg daily for 6 months",[18],"Drug: Rivaroxaban 20 MG Oral Tablet",[20,27],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Apixaban 5MG","100 CVT patients will receive apixaban 5mg Bid for 6 months. We will assess the Proportion of subjects who have partial or complete venous recanalization by Day 180 the rate of drug hemorrhagic complications using the PLATO bleeding definition, and the rates of patients who achieved a favorable outcome with (mRS = 0-2) after one week and after 180 days in a face-to-face interview in the outpatient clinic, Proportion of subjects with recurrent venous thromboembolism (any thrombosis at a new site, including cerebral venous thrombosis in a separate location from the index event) at Day 180 or the end of anticoagulation, whichever is sooner, rates of a composite of pulmonary embolism, DVT, myocardial infarction, and death due to vascular events after 180 days of follow-up, the MoCA, HIT-6 by 180 days, the rate of treatment-related adverse effects assessed by a follow-up questionnaire",[9],[26],"group A",{"type":21,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"Rivaroxaban 20 MG Oral Tablet","100 CVT patients will receive Rivaroxaban 20mg daily for 6 months. We will assess the Proportion of subjects who have partial or complete venous recanalization by Day 180 the rate of drug hemorrhagic complications using the PLATO bleeding definition, and the rates of patients who achieved a favorable outcome with (mRS = 0-2) after one week and after 180 days in a face-to-face interview in the outpatient clinic, Proportion of subjects with recurrent venous thromboembolism (any thrombosis at a new site, including cerebral venous thrombosis in a separate location from the index event) at Day 180 or the end of anticoagulation, whichever is sooner, rates of a composite of pulmonary embolism, DVT, myocardial infarction, and death due to vascular events after 180 days of follow-up, the MoCA, HIT-6 by 180 days, the rate of treatment-related adverse effects assessed by a follow-up questionnaire",[15],[32],"group B",[34],{"name":35,"affiliation":36,"role":37},"mohamed G. Zeinhom, MD","neurology department kafr el-sheikh university","PRINCIPAL_INVESTIGATOR",[39,44],{"name":35,"role":40,"phone":41,"phoneExt":42,"email":43},"CONTACT","2001009606828",null,"mohamed_gomaa@med.kfs.edu.eg",{"name":45,"role":40,"phone":46,"phoneExt":42,"email":47},"sherihan R. ahmed, MD","2001113432342","sherihan_rezq@med.kfs.edu.eg",[49],{"facility":50,"status":51,"city":52,"state":42,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"Kafr Elsheikh University Hospital","RECRUITING","Kafr ash Shaykh","33511","Egypt","EG",{"type":57,"coordinates":58},"Point",[59,60],30.93991,31.11174,{"lat":60,"lon":59},[63,64],{"name":35,"role":40,"phone":41,"phoneExt":42,"email":43},{"name":45,"role":40,"phone":65,"phoneExt":42,"email":47},"2001007481842",{"type":37,"investigatorFullName":67,"investigatorTitle":68,"investigatorAffiliation":5,"oldNameTitle":42,"oldOrganization":42},"Mohamed G. zeinhom, MD","principal investigator","100556900","phase-3-rivaroxaban-versus-apixaban-in-cerebral-venous-thrombosis-100556900",false,"NCT06531122","Rivaroxaban Versus Apixaban in Cerebral Venous Thrombosis","Rivaroxaban Versus Apixaban in Cerebral Venous Thrombosis, a Randomized Controlled Trial","Inclusion Criteria:\n\n1. Patients aged 18 and above\n2. New diagnosis of symptomatic cerebral venous thrombosis as confirmed on CT\u002FCT venogram or MRI\u002FMR venogram\n3. Ability to randomize within 14 days of neuroimaging-confirmed diagnosis\n4. The treating clinician is of the opinion that the patient is appropriate for oral anticoagulation as per the standard of care\n5. The patient or legally authorized representative is able to give written informed consent\n\nExclusion Criteria:\n\n1. The patient has known antiphospholipid antibody syndrome with a previous history of venous or arterial thrombosis\n2. The patient is anticipated to require invasive procedures (e.g., lumbar puncture, thrombectomy, hemicraniectomy) prior to initiation of oral anticoagulation\n3. Patient is unable to swallow due to depressed level of consciousness\n4. Impaired renal function (i.e., CrCl \\\u003C 30 mL\u002Fmin using CockroftGault equation)\n5. Pregnancy; if a woman is of childbearing potential a urine or serum beta human chorionic gonadotropin (β-hCG) test is positive\n6. Breastfeeding at the time of randomization\n7. Bleeding diathesis or other contraindication to anticoagulation\n8. Any concurrent medical condition requiring mandatory antiplatelet or anticoagulant use\n9. Concomitant use of strong CYP3A4 inducers (e.g., ongoing use of dilantin, carbamazepine, HIV protease inhibitors) or CYP3A4 inhibitors (e.g., diltiazem, ketoconazole)\n10. Patient has a severe or fatal comorbid illness that will prevent improvement","ALL","18 Years","75 Years",{"count":80,"type":81},200,"ESTIMATED","INTERVENTIONAL",[84],"PHASE3","Along with the current clinical trial, the efficacy and safety of a 20 mg rivaroxaban administered within 24 hours of randomization after having first-ever cerebral venous thrombosis compared to apixaban 5mg Bid were assessed through rate of recurrent VTE, mRS, rate of venous recanalization, HIT score, MoCA test, and central and peripheral heamoragic complications.",[87],"Cerebral Venous Thrombosis",[89,90,87,54,91],"apixaban,","rivaroxiban","Middle east","2024-08-16",{"date":94,"type":95},"2024-08-19","ACTUAL",{"date":97,"type":95},"2021-08-01",{"date":99,"type":81},"2024-09-20",{"name":5,"class":6},1]